FindMyKOL
Clinical trialNCT04875754CompletedPhase 1/2Interventional

A Study Evaluating the Safety, Tolerability, and Range of Biologically Active Doses of ICM-203 in Mild to Moderate Knee Osteoarthritis

NCT04875754 is a phase 1/2 interventional trial sponsored by ICM Biotech Australia Pty Ltd.. As of 21 Nov 2026, it is completed. It studies Placebo in Osteoarthritis, Knee. The registry lists an enrollment of 12 participants at 2 sites in 1 country. The registry lists a start date of 17 Mar 2022 and a primary completion date of 20 Feb 2026.

SponsorICM Biotech Australia Pty Ltd.Enrollment12Osteoarthritis, Knee
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04875754
FieldValue
Registry IDNCT04875754
StatusCompleted
PhasePhase 1/2
Study typeInterventional trial
Lead sponsorICM Biotech Australia Pty Ltd.
Enrollment12
Registered sites2
Countries1
ConditionsOsteoarthritis, Knee
DrugsPlacebo
Start17 Mar 2022
Primary completion20 Feb 2026
Study completion20 Feb 2026
Last update posted3 Sept 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine the safety, tolerability, and activity of ICM-203, a recombinant adeno-associated viral (AAV) vector that expresses a therapeutic gene that promotes cartilage formation, reduces joint inflammation and pain, as well as improves joint physical function, by injecting escalating doses of ICM-203 or matching placebo into the knee of subjects with mild to moderate knee osteoarthritis (OA).

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia2 sites
  • Royal Adelaide Hospital

    Adelaide, South Australia

  • Barwon Health

    Geelong, Victoria

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Placebo
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT04875754

Each answer restates registry values shown on this page.

What is NCT04875754?

NCT04875754 is a phase 1/2 interventional trial sponsored by ICM Biotech Australia Pty Ltd.. It studies Placebo in Osteoarthritis, Knee.

Who leads NCT04875754?

The registry names Alison Heald, MD (study director, ICM Co. Ltd.) as the overall official.

Where does NCT04875754 run?

The registry lists 2 sites in 1 country. Every site with a stated country is in one country: Australia.

Which drugs does NCT04875754 study?

The registered drug and biological interventions are Placebo.

When did NCT04875754 end?

The registry lists a primary completion date of 20 Feb 2026 and a study completion date of 20 Feb 2026. The sponsor last updated the record on 3 Sept 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.